转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

Clinica Chimica Acta：评价两种血清游离轻链定量方法并在临床实验室进行转换免疫分析

2020-08-09 MedSci原创 MedSci原创

血清游离轻链定量方法
关注

血清游离轻链（sFLC）定量是浆细胞发育不良的关键。目前，有几种检测方法可供使用，在某些实验室中，更换sFLC方法可能是有利的。

血清游离轻链（sFLC）定量是浆细胞发育不良的关键。目前，有几种检测方法可供使用，在某些实验室中，更换sFLC方法可能是有利的。本研究对临床实验室在10个月期间收到的样本同时进行了Freelite和Seralite，并比较了定量及其对患者结果解释的影响。

189例患者包括多发性骨髓瘤(MM)及相关浆细胞癌、不明原因单克隆性甘氏病(MGUS)、淀粉样变和肾脏损害患者。评估两种方法之间sFLC定量和临床一致性。

诊断时的临床一致性很强（κ= 0.647，p <.01），监测时的临床一致性是中度（κ= 0.591，p <.01）。 MM，相关血浆疾病和MGUS的一致性良好，而AL淀粉样变性的一致性较差。 案例研究说明了骨髓瘤疾病活动模式的一致性。布兰德·阿特曼（Bland-Atman）图显示平均偏差较小，但随着FLC浓度的增加，方法之间的差异也越来越大。Passing-Bablok分析证实了方法之间定量的系统差异。

尽管在定量方面存在差异，但总的来说，不同的sFLC平台在临床解释方面是一致的。作为一种快速的测试，不需要大型和昂贵的分析仪，Seralite可能在某些实验室适用性较高，以实现内部测试。

原始出处：

Jennifer L.J.Heaney，Felix Ackermann，Evaluation of two serum free light chain quantitation methods, Freelite and Seralite, in the clinical laboratory with a view to switching immunoassay

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1928173, encodeId=310819281e355, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri Mar 05 20:54:48 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850017, encodeId=59e1185001e9a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Apr 04 20:54:48 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941569, encodeId=77da1941569fc, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Jan 12 11:54:48 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444643, encodeId=6aca1444643db, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Aug 11 13:54:48 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
    2021-03-05 jiangfeng5067

    #免疫分析#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1928173, encodeId=310819281e355, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri Mar 05 20:54:48 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850017, encodeId=59e1185001e9a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Apr 04 20:54:48 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941569, encodeId=77da1941569fc, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Jan 12 11:54:48 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444643, encodeId=6aca1444643db, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Aug 11 13:54:48 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
    2021-04-04 windight

    #CTA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1928173, encodeId=310819281e355, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri Mar 05 20:54:48 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850017, encodeId=59e1185001e9a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Apr 04 20:54:48 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941569, encodeId=77da1941569fc, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Jan 12 11:54:48 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444643, encodeId=6aca1444643db, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Aug 11 13:54:48 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
    2021-01-12 liuhuangbo

    #临床实验#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1928173, encodeId=310819281e355, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri Mar 05 20:54:48 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850017, encodeId=59e1185001e9a, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Apr 04 20:54:48 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941569, encodeId=77da1941569fc, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Tue Jan 12 11:54:48 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444643, encodeId=6aca1444643db, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Aug 11 13:54:48 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
    2020-08-11 huagfeg

    #评价#

    0